Daptomycin clearance during modeled continuous renal replacement therapy

被引:60
作者
Churchwell, Mariann D.
Pasko, Deborah A.
Mueller, Bruce A.
机构
[1] Univ Toledo, Coll Pharm, Dept Pharm Practice, Toledo, OH 43606 USA
[2] Univ Michigan, Renal Replacement Therapy Kinet Study Grp, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Hlth Syst, CS Mott Childrens Hosp, Dept Pharm Serv, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Coll Pharm, Dept Clin Sci, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Hlth Syst, Dept Pharm Serv, Ann Arbor, MI 48109 USA
关键词
daptomycin; continuous renal replacement therapy; continuous hemofiltration; continuous hemodialysis; acute renal failure; pharmacokinetics;
D O I
10.1159/000097078
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background/Aims: Pharmacotherapy in critically ill patients receiving continuous renal replacement therapies (CRRT) is challenging due to the lack of published information to base dosing regimens. Methods: Daptomycin's transmembrane clearance during continuous hemofiltration and hemodialysis was assessed using an in vitro model with AN69 and polysulfone hemodiafilters at varying ultrafiltrate and dialysate flow rates (1, 2, 3 and 6 l/h). Results: During continuous hemofiltration, mean daptomycin sieving coefficient ranged from 0.14 to 0.20. Transmembrane clearances were significantly different between filter types for ultrafiltration rates of 2, 3 and 6 l/h. For continuous hemodialysis, mean daptomycin saturation coefficient ranged from 0.05 to 0.15. AN69-based daptomycin clearances were significantly lower than polysulfone values at dialysate flow rates of 2, 3 and 6 l/h. Conclusion: The extent of daptomycin's transmembrane clearance is dependent on hemodiafilter type, dialysate and ultrafiltration rates. CRRT with high ultrafiltrate or dialysate rates may result in substantial daptomycin clearances. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:548 / 554
页数:7
相关论文
共 35 条
[1]
Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters:: Evaluation of the sieving coefficient [J].
Arzuaga, A. ;
Isla, A. ;
Gascon, A. R. ;
Maynar, J. ;
Corral, E. ;
Pedraz, J. L. .
BLOOD PURIFICATION, 2006, 24 (04) :347-354
[2]
Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates [J].
Brunet, S ;
Leblanc, M ;
Geadah, D ;
Parent, D ;
Courteau, S ;
Cardinal, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :486-492
[3]
CHURCHWELL MD, 2005, AM SOC NEPHROL
[4]
CLARK WR, 1994, J AM SOC NEPHROL, V4, P1413
[5]
MEMBRANE ADSORPTION OF BETA(2)-MICROGLOBULIN - EQUILIBRIUM AND KINETIC CHARACTERIZATION [J].
CLARK, WR ;
MACIAS, WL ;
MOLITORIS, BA ;
WANG, NHL .
KIDNEY INTERNATIONAL, 1994, 46 (04) :1140-1146
[6]
High-volume haemofiltration in human septic shock [J].
Cole, L ;
Bellomo, R ;
Journois, D ;
Davenport, P ;
Baldwin, I ;
Tipping, P .
INTENSIVE CARE MEDICINE, 2001, 27 (06) :978-986
[7]
*CUB PHARM INC, 2003, CUB DAPT INJ PACK IN
[8]
Population pharmacokineties of daptomycin [J].
Dvorchik, B ;
Arbeit, RD ;
Chung, J ;
Liu, S ;
Knebel, W ;
Kastrissios, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :2799-2807
[9]
DVORCHIK B, 2002, INT C ANT AG CHEM
[10]
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects [J].
Dvorchik, BH ;
Brazier, D ;
DeBruin, MF ;
Arbeit, RD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1318-1323